Angiotech appoints Chris Dennis as Senior Vice President, Sales and Marketing



    VANCOUVER, April 3 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, today
announced the appointment of Chris Dennis as Senior Vice President, Sales and
Marketing.
    Mr. Dennis brings to Angiotech a broad background in marketing, sales and
general management in the health care sector including over 17 years of
experience working for various subsidiaries of Johnson & Johnson (J&J).
    Prior to joining Angiotech, Mr. Dennis was Global President of J&J's
OrthoNeutrogena company (pharmaceuticals and aesthetic devices), where he was
responsible for overall strategy and business growth initiatives. Previously,
he held the position of Vice President, Marketing & Sales for Janssen Ortho,
Inc. (pharmaceuticals), where he managed the sales and marketing of a wide
range of prescription medications. Mr. Dennis also held the position of
President, LifeScan Canada Ltd. (medical devices), where he oversaw the sales,
marketing and distribution of diagnostic products for people with diabetes. He
also held a number of sales and management roles at McNeil Consumer Products,
a J&J company, and Bristol Myers Products Canada.
    "This time last year, Angiotech was a company with significant expertise
in R&D and a substantial intellectual property portfolio. Today, we have built
on that foundation and grown to become a fully integrated and commercialized
specialty pharmaceutical and medical device company. With our comprehensive
manufacturing, sales and marketing capabilities, we're pleased that Angiotech
is attracting industry leaders like Chris to our senior management team," said
Dr. William Hunter, President and CEO of Angiotech.
    As Senior Vice President, Sales and Marketing, Mr. Dennis will be focused
on building a global sales and marketing organization with a commercialization
strategy that includes Angiotech's five identified focus markets. Angiotech
anticipates a number of important product launches in 2007, including the
Quill(R) SRS wound closure system and Angiotech's anti-infective 5-FU CVC.
    "Recognizing Chris' extensive experience in both the pharmaceutical and
medical device industries, we're confident he will help us build a strong
global sales and marketing division, and we're excited that he shares our
vision of a fully-commercialized Angiotech," added Dr. Hunter.

    Note on Forward Looking Statements
    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities legislation.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results, events or developments to
be materially different from any future results, events or developments
expressed or implied by such forward-looking statements. Many such risks,
uncertainties and other factors are taken into account as part of our
assumptions underlying these forward-looking statements and include, among
others, the following; general economic and business conditions, both
nationally and in the regions in which we operate; market demand;
technological changes that could impact our existing products or our ability
to develop and commercialize future products; competition; existing
governmental regulations and changes in, or the failure to comply with,
governmental regulations; decisions, and the timing of decisions, made by
health regulatory agencies regarding approval of our technology and products;
the requirement for substantial funding to conduct research and development
and to expand commercialization activities; and any other factors that may
affect performance. In addition, our business is subject to certain operating
risks that may cause the actual results expressed or implied by the
forward-looking statements in this report to differ materially from our actual
results. These operating risks include; poor performance of the product in the
clinical setting; adverse events related to the use of the product; improper
estimation of the size of the product markets; adverse results or unexpected
delays in clinical development processes; our ability to attract and retain
qualified personnel; our ability to successfully complete preclinical and
clinical development of our products; changes in business strategy or
development plans; our failure to obtain patent protection for discoveries;
loss of patent protection resulting from third party challenges to our
patents; commercialization limitations imposed by patents owned or controlled
by third parties; our ability to obtain rights to technology from licensors;
liability for patent claims and other claims asserted against us; our ability
to obtain and enforce timely patent and other intellectual property protection
for our technology and products; the ability to enter into, and to maintain,
corporate alliances relating to the development and commercialization of our
technology and products; market acceptance of our technology and products; our
ability to successfully manufacture, market and sell our products; the
continued availability of capital to finance our activities; our ability to
continue to integrate into our business the operations of American Medical
Instruments Holdings, Inc. and our ability to achieve the operational and
other synergies and the other commercial or financial benefits expected as a
result of that acquisition; and any other factors referenced in our annual
information form and other filings with the applicable Canadian securities
regulatory authorities or the SEC.
    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements. We
disclaim any obligation to update any such factors or to publicly announce the
result of any revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.

    Quill(R) is a registered trademark of Quill Medical, Inc., a wholly-owned
subsidiary of Angiotech Pharmaceuticals, Inc.(C) 2007 Angiotech
Pharmaceuticals, Inc. All rights reserved.

    About Angiotech
    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with 17 facilities in 6 countries and over 1,500
dedicated employees. Angiotech discovers, develops and markets innovative
treatment solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find out more
about Angiotech (NASDAQ:   ANPI, TSX: ANP), please visit our website at
www.angiotech.com.





For further information:

For further information: Janet Craig, VP, Investor Relations and
Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-6933,
jcraig@angio.com; Jodi Regts, Manager, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930,
jregts@angio.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890